A tutorial on target-mediated drug disposition (TMDD) models

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 6, 2015, Pages 324-337

  Dua, P ^a   Hawkins, E ^a,b   Van Der Graaf, P H ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITY; COMPARTMENT MODEL; DRUG DISPOSITION; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; MATHEMATICAL MODEL; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; QUASI STEADY STATE MODEL; REBOUND; REVIEW; TARGET MEDIATED DRUG DISPOSITION MODEL;

EID: 84936817551     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.41     Document Type: Review

References (84)

1. Levy, G., Pharmacologic target-mediated drug disposition. Clin. Pharmacol. Ther. 56, 248-252 (1994).
2. Krause, A., &, Lowe, P.J., Visualization and communication of pharmacometric models with Berkeley Madonna. CPT Pharmacometrics Syst. Pharmacol. 3, 1-20 (2014).
3. Kenakin, T., A Pharmacology Primer: Theory, Application, and Methods (Elsevier Academic Press, San Diego & London, 2004).
4. Lauffenburger, D.A., &, Linderman J.J., Receptor: Models for Binding, Trafficking, and Signalling (Oxford University Press, New York, 1996).
5. Wagner, J.G., Biopharmaceutics and Relevant Pharmacokinetics (Drug Intelligence Publications, Hamilton Press, Fernandina Beach, FL, 1972).
6. Sugiyama, Y., &, Hanano, M., Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm. Res. 6 192-202 (1989).
7. Abraham, A.K., Kagan, L,., Kumar, S., &, Mager, D.E., Type 1 interferon receptor is a primary regulator of target-mediated drug disposition of interferon-β in mice. JPET 334, 327-332 (2010).
8. Mager, D., &, Jusko, W., General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28, 507-532 (2001).
9. Zhao, L., et al,. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development. J. Pharm. Sci. 101, 4367-4382 (2012).
10. Dostalek, M., et al,. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modeling of monoclonal antibodies. Clin. Pharmacokinet. 52, 83-124 (2013).
11. Aston, P.J., Derks, G., Raji, A., Agoram B.M., &, van der Graaf P.H., Mathematical analysis of the pharmokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J. Theor. Biol. 281, 113-121 (2011).
12. Kenakin, T.P., Pharmacology in Drug Discovery: Understanding Drug Response (Elsevier Academic Press, London, Waltham, MA, & San Diego, 2012).
13. Chimalakonda, A.P., et al,. Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development. AAPS J. 15, 717-727 (2013).
14. Aston, P.J., et al,. A mathematical analysis of rebound in a target-mediated drug disposition model: I. Without feedback. J. Math. Biol.; e-pub ahead of print 2013.
15. th Noordwijkerhout Symposium on Pharmacokinetics, Pharmacodynamics and Systems Pharmacology, Netherlands (2014).
16. Mager, D.E., &, Krzyzanski, W., Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm. Res. 22, 1589-1596 (2005).
17. Gibiansky, L., Gibiansky, E., Kakkar, T., &, Ma, P., Approximations of the target-mediated drug disposition model and identifiability of model parameters. J. Pharmacokinet. Pharmacodyn. 35, 573-591 (2008).
18. Peletier, L.A., &, Gabrielsson, J., Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J. Pharmacokinet. Pharmacodyn. 39, 429-451 (2012).
19. Marathe, A., Krzyzanski, W., &, Mager, D.E., Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J. Pharmacokinet. Pharmacodyn. 36, 199-219 (2009).
20. Davda, J.P., &, Hansen, R.J., Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. mAbs 2, 576-588 (2010).
21. Ma, P., Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. Pharm. Res. 29, 866-882 (2011).
22. Yan, X., Mager, D.E., &, Krzyzanski, W., Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J. Pharmacokinet. Pharmacodyn. 37, 25-47 (2010).
23. Gibiansky, L., &, Gibiansky, E., Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J. Pharmacokinet. Pharmacodyn. 36, 341-351 (2009).
24. Yan, X., &, Krzyzanski, W., Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. J. Pharmacokinet. Pharmacodyn. 39, 141-146 (2012).
25. Olsson-Gisleskog, et al,. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin. Pharmacokinet. 46, 159-173 (2007).
26. Krippendorff, B.F., et al,. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J. Pharmacokinet. Pharmacodyn. 36, 239-260 (2009).
27. Kagan, L., et al,. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm. Res. 29, 490-499 (2012).
28. Gibiansky, L., &, Gibiansky, E., Target-mediated drug disposition model for drugs that bind to more than one target. J. Pharmacokinet. Pharmacodyn. 37, 323-346 (2010).
29. Yan, X., Chen, Y., &, Krzyzanski, W., Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J. Pharmacokinet. Pharmacodyn. 39, 543-560 (2012).
30. Krippendorff, B.F., Oyarzún, D.A., &, Huisinga, W., Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modeling. J. Pharmacokinet. Pharmacodyn. 39, 125-139 (2012).
31. Jager, E., et al,. Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS One 6, e24265 (2011).
32. Xiao, J.J., et al,. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 12, 646-657 (2010).
33. Perez Ruixo, J.J., Ma, P., &, Chow, A.T., The utility of modeling and simulation approaches to evaluate immunogenicity effect on therapeutic protein pharmacokinetics. AAPS J. 15, 172-182 (2013).
34. Lowe, P.J., Tannenbaum, S., Wu, K., Lloyd, P., &, Sims, J., On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin. Pharmacol. Toxicol. 106, 195-209 (2009).
35. Retlich, S., et al,. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J. Clin. Pharmacol. 50, 873-885 (2010).
36. Landersdorfer, C.B., He, Y.L., &, Jusko, W.J., Mechanism-based population pharmacokinetic modeling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. Br. J. Clin. Pharmacol. 73, 391-401 (2011).
37. Kagan, L., Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins. Drug Metab. Dispos.; e-pub ahead of print 2014.
38. Grimm, H.P., Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J. Pharmacokinet. Pharmacodyn. 36, 407-420 (2009).
39. Agoram, B.M., Use of pharmacokinetic/pharmacodynamic modeling for starting dose selection in first-in-human trials of high-risk biologics. Br. J. Clin. Pharmacol. 67, 153-160 (2008).
40. Mahmood, I., Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J. Pharm. Sci. 98, 3850-3861 (2009).
41. Kagan, L., Abraham, A.K., Harrold, J.M., &, Mager, D.E., Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type 1 interferons. Pharm. Res. 27, 920-932 (2010).
42. Luu, K.T., Bergqvist, S., Chen, E., Hu-Lowe, D., &, Kraynov, E., A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. JPET 341, 702-708 (2012).
43. Yu, J., et al,. From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J. 13, 169 (2011).
44. Chen, P,. et al. Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm. Res.; e-pub ahead of print 2014.
45. Cao, Y., &, Jusko, W.J., Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. J. Pharmacokinet. Pharmacodyn.; e-pub ahead of print 2014.
46. Kakkar, T., et al,. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm. Res. 28, 2530-2542 (2011).
47. Marathe, A., Van Wart, S., &, Mager, D.E., Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 38, 223-235 (2011).
48. Krzyzanski, W., &, Wyska, E., Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn-Schmiedeberg's Arch. Pharmacol. 377, 637-645 (2008).
49. Tang, C., &, Prueksaritanont, T., Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of "free" and "total" drug and target. Pharm. Res. 28, 2447-2457 (2011).
50. Mager, D.E., Target-mediated drug disposition and dynamics. Biochem. Pharmacol. 72, 1-10 (2006).
51. Peletier, L.A., &, Gabrielsson, J., Dynamics of target-mediated drug disposition. Eur. J. Pharm. Sci. 38, 445-464 (2009).
52. Chen, T., Mager, D.E., &, Kagan, L., Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm. Res. 30, 751-760 (2013).
53. Meno-Tetang, G.M., &, Lowe, P.J., On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin. Pharmacol. Toxicol. 96, 182-192 (2005).
54. Betts, A.M., et al,. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. JPET 333, 2-13 (2010).
55. Woo, S., Krzyzanski, W., &, Jusko, W.J., Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J. Pharmacokinet. Pharmacodyn. 34, 849-868 (2007).
56. Samtani, M.N., et al,. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects. J. Clin. Pharmacol. 49, 336-350 (2009).
57. Gao, W., &, Jusko, W.J., Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. JPET 336, 881-890 (2011).
58. Abraham, A.K., Krzyzanski, W., &, Mager, D.E., Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J. 9, Article 20 (2007).
59. Agoram, B.M., Martin, S.M., &, van der Graaf, P.H., The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational research of biologics. Drug Discov. Today 12, 1018-1024 (2007).
60. Chakraborty, A., et al,. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin. Pharmacokinet. 51, e1-e18 (2012).
61. Yan, X., et al,. Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human epoetin alfa and the Biosimilar HX575. J. Clin. Pharmacol. 52, 1624-1644 (2012).
62. Lowe, P.J., Applying physiological and biochemical concepts to optimize biological drug development. Clin. Pharmacol. Ther. 87, 492-496 (2010).
63. Gibiansky, L., et al,. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin. Pharmacokinet 51, 247-260 (2012).
64. Gibiansky, L., &, Frey, N., Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J. Pharmacokinet. Pharmacodyn. 39, 5-16 (2012).
65. Lobo, E.D,., Soda, D.M., &, Balthasar, J.P., Application of pharmacokinetic/pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice. J. Pharm. Sci. 92 (8), 1665-1676 (2003).
66. Gao, W., &, Jusko, W.J., Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab. Dispos. 40, 990-997 (2012).
67. Thai, H.T., et al,. A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. Br. J. Clin. Pharmacol. 72 (3), 402-414 (2011).
68. Wang, Y.M., et al,. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 12, 729-740 (2010).
69. Ait-Oudia, S., Scherrmann, J.M., &, Krzyzanski, W., Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats. J. Pharmacol. Exp. Ther. 334, 897-910 (2010).
70. Jin, F., &, Krzyzanski, W., Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS Pharm. Sci. 6, Article 9 (2004).
71. Marathe, A., Peterson, M.C., &, Mager, D.E., Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J. Pharmacol. Exp. Ther. 326, 555-562 (2008).
72. Kagan, L., &, Mager, D.E., Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab. Dispos. 41, 248-255 (2013).
73. Segrave, A.M., et al,. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J. Pharmacol. Exp. Ther. 309, 1083-1092 (2004).
74. Mager, D.E., et al,. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J. Pharmacol. Exp. Ther. 307, 969-976 (2003).
75. Mager, D.E., &, Jusko, W.J., Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-β 1a in humans. Pharm. Res. 19, 1537-1543 (2002).
76. Mager, D.E., et al,. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-β 1a in monkeys. J. Pharmacol. Exp. Ther. 306, 262-270 (2003).
77. Eppler, S.M., et al,. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther. 72, 20-32 (2002).
78. Wiczling, P., et al,. Population pharmacokinetic modeling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin. Pharmacokinet. 48, 817-826 (2009).
79. Ng, C.M., et al,. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm. Res. 23, 95-103 (2006).
80. Vexler, V., et al,. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys. mAbs 5, 776-786 (2013).
81. Vugmeyster, Y., et al,. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B. Applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design. mAbs 5, 373-383 (2013).
82. Yamazaki, S., et al,. Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors. Drug Metab. Dispos. 41, 1285-1294 (2013).
83. McNamara, P.J., et al,. Effect of plasma protein and tissue binding on the time course of drug concentration in plasma. J. Pharmacokinet. Biopharm. 7, 195-206 (1979).
84. Oie, S., et al,. Effect of saturable binding on the pharmacokinetics of drugs: a simulation. J. Pharm. Pharmacol. 32, 471-477 (1980).